NJ Flexi Cap Fund
The Scheme is seeks to generate long term capital appreciation by investing in equity and equity related instruments across market capitalizations.
Growthvine rating: 2/5 — ranked #34 of 56 in category.
Fund basics
| Category | Equity: Flexi Cap |
|---|
| NAV | ₹12.14 (as of 2026-10-23) |
|---|
| AUM | ₹2,572 Cr |
|---|
| Expense ratio | 1.70% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Dhaval Patel |
|---|
| Exit load | 0 |
|---|
Performance & risk
| Sharpe ratio | 0.17 |
|---|
| Standard deviation | 17.17% |
|---|
| Max drawdown | −28.39% |
|---|
| Alpha | -1.52 |
|---|
| Beta | 1 |
|---|
Over 5 years, captured 91.7% of Nifty 500's upside and 97.8% of its downside.
Market cap allocation
| Large cap | 52.1% |
|---|
| Mid cap | 30.3% |
|---|
| Small cap | 17.5% |
|---|
Concentration
| Top 5 holdings | 24.0% |
|---|
| Top 10 holdings | 42.4% |
|---|
| Total holdings | 51 |
|---|
| Index overlap | 21.6% |
|---|
| Active share | 78.4% |
|---|
Top holdings
- Torrent Pharmaceuticals Ltd. — 5.6%
- Bosch Ltd — 5.2%
- Dr. Lal Pathlabs Limited — 4.9%
- Marico Limited — 4.2%
- Eicher Motors Ltd. — 4.2%
- ICICI Bank Ltd. — 4.2%
- Britannia Industries Ltd. — 3.8%
- Cipla Ltd. — 3.6%
- Sun Pharmaceutical Industries Ltd. — 3.5%
- ITC Ltd — 3.3%
Top sectors
- Pharma & Biotech — 22.0%
- Automobile — 14.4%
- Banking & Financial — 11.8%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | −9.1% | Q3 | #37 of 50 |
| 2025 | −2.9% | Q4 (Bottom) | #38 of 43 |
| 2024 | 13.7% | Q4 (Bottom) | #38 of 42 |